DDInter1442 DDInter1376
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Phenobarbital {u} (Compound) resembles {v} (Compound) Primidone
Phenobarbital {u} (Compound) resembles {v} (Compound) Methsuximide
Phenobarbital {u} (Compound) treats {v} (Disease) epilepsy syndrome
Phenobarbital {u} (Compound) binds {v} (Gene) ABCC3
Phenobarbital {u} (Compound) causes {v} (Side Effect) Mental disability
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Sunitinib
Phenobarbital (Compound) resembles Primidone (Compound)
Phenobarbital (Compound) resembles Methsuximide (Compound)
Phenobarbital (Compound) treats epilepsy syndrome (Disease)
Phenobarbital (Compound) binds ABCC3 (Gene)
Phenobarbital (Compound) causes Mental disability (Side Effect)
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Phenobarbital may lead to a major life threatening interaction when taken with Sunitinib